Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00659165|
Recruitment Status : Completed
First Posted : April 16, 2008
Results First Posted : October 5, 2011
Last Update Posted : January 19, 2018
|Condition or disease||Intervention/treatment|
|Diabetes Mellitus||Drug: Insulin Detemir Drug: Insulin Glargine|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Exploration of the Weight Neutral Effects of Insulin Detemir Compared to Insulin Glargine: A Measure of Satiety and Calories Consumed in Type 1 Diabetes|
|Study Start Date :||April 2008|
|Primary Completion Date :||December 2010|
|Study Completion Date :||January 2011|
Drug: Insulin Detemir
Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
Other Name: Levemir
Drug: Insulin Glargine
Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
Other Name: Lantus
- Calories Consumed After Fast. [ Time Frame: Measured after a 24 hour fast, after treatment with study insulin for at least 3 weeks ]Total energy ingested following the 24 hour fast.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00659165
|United States, New Mexico|
|University of New Mexico Health Sciences Center|
|Albuquerque, New Mexico, United States, 87131|
|Principal Investigator:||Mark Burge, M.D.||University of New Mexico, Department of Internal Medicine, Division of Endocrinology|
|Study Director:||Stephen Mitchell, D.O.||University of New Mexico, Department of Internal Medicine, Division of Endocrinology|